|
1
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohe Y, Ohashi Y, Kubota K, et al:
Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar
|
|
3
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nana-Sinkam SP and Powell CA: Molecular
biology of lung cancer: diagnosis and management of lung cancer,
3rd ed: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest. 143(Suppl 5): e30S–e39S. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
8
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okamoto I, Yoshioka H, Morita S, et al:
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel
plus carboplatin in chemotherapy-naïve patients with advanced
non-small-cell lung cancer: results of a west Japan oncology group
study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanna N, Shepherd FA, Fossella FV, et al:
Randomized phase III trial of pemetrexed versus docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pujol JL, Barlesi F and Daurès JP: Should
chemotherapy combinations for advanced non-small cell lung cancer
be platinum-based? A meta-analysis of phase III randomized trials.
Lung Cancer. 51:335–345. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gridelli C: The ELVIS trial: a phase III
study of single-agent vinorelbine as first-line treatment in
elderly patients with advanced non-small cell lung cancer. Elderly
Lung Cancer Vinorelbine Italian Study. Oncologist. 6(Suppl 1):
S4–S7. 2001. View Article : Google Scholar
|
|
13
|
Butts CA, Ding K, Seymour L, et al:
Randomized phase III trial of vinorelbine plus cisplatin compared
with observation in completely resected stage IB and II
non-small-cell lung cancer: updated survival analysis of JBR-10. J
Clin Oncol. 28:29–34. 2010. View Article : Google Scholar :
|
|
14
|
Dunant A, Pignon JP and Le Chevalier T:
Adjuvant chemotherapy for non-small cell lung cancer: contribution
of the International Adjuvant Lung Trial. Clin Cancer Res.
11:5017s–5021s. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Douillard JY, Rosell R, De Lena M, et al:
Adjuvant vinorelbine plus cisplatin versus observation in patients
with completely resected stage IB–IIIA non-small-cell lung cancer
(Adjuvant Navelbine International Trialist Association [ANITA]): a
randomised controlled trial. Lancet Oncol. 7:719–727. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakagawa M, Tanaka F, Tsubota N, Ohta M,
Takao M and Wada H; West Japan Study Group for Lung Cancer Surgery.
A randomized phase III trial of adjuvant chemotherapy with UFT for
completely resected pathological stage I non-small-cell lung
cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG) -
the 4th study. Ann Oncol. 16:75–80. 2005. View Article : Google Scholar
|
|
17
|
Kato H, Ichinose Y, Ohta M, et al: A
randomized trial of adjuvant chemotherapy with uracil-tegafur for
adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsumoto S, Igishi T, Hashimoto K, et al:
Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT
against non-small cell lung cancer. Int J Oncol. 25:1311–1318.
2004.PubMed/NCBI
|
|
19
|
Igishi T, Shigeoka Y, Yasuda K, et al: UFT
plus vinorelbine in advanced non-small cell lung cancer: a phase I
and an elderly patient-directed phase II study. J Thorac Oncol.
4:376–382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kodani M, Kinoshita N, Ueda Y, Suyama H,
Sumikawa T, Makino H, Kurai J, Matsumoto S, Igishi T and Shimizu E:
Phase II study of S-1 and vinorelbine in patients with advanced
non-small cell lung cancer. Eur J Cancer. 47(Suppl 1): S6202011.
View Article : Google Scholar
|
|
21
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
23
|
Takata M, Chikumi H, Miyake N, et al: Lack
of AKT activation in lung cancer cells with EGFR mutation is a
novel marker of cetuximab sensitivity. Cancer Biol Ther.
13:369–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Das AK, Chen BP, Story MD, Sato M, Minna
JD, Chen DJ and Nirodi CS: Somatic mutations in the tyrosine kinase
domain of epidermal growth factor receptor (EGFR) abrogate
EGFR-mediated radioprotection in non-small cell lung carcinoma.
Cancer Res. 67:5267–5274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khayat D, Rixe O, Brunet R, et al:
Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient
dose escalation study design. Cancer Chemother Pharmacol.
54:193–205. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dickgreber NJ, Fink TH, Latz JE, Hossain
AM, Musib LC and Thomas M: Phase I and pharmacokinetic study of
pemetrexed plus cisplatin in chemonaive patients with locally
advanced or metastatic malignant pleural mesothelioma or non-small
cell lung cancer. Clin Cancer Res. 15:382–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirata K, Horikoshi N, Aiba K, et al:
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor
drug. Clin Cancer Res. 5:2000–2005. 1999.PubMed/NCBI
|
|
29
|
Muggia FM, Wu X, Spicer D, et al: Phase I
and pharmacokinetic study of oral UFT, a combination of the
5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res.
2:1461–1467. 1996.PubMed/NCBI
|
|
30
|
Wu X, Sooman L, Lennartsson J, Bergström
S, Bergqvist M, Gullbo J and Ekman S: Microtubule inhibition causes
epidermal growth factor receptor inactivation in oesophageal cancer
cells. Int J Oncol. 42:297–304. 2013.
|
|
31
|
Okabe T, Okamoto I, Tsukioka S, et al:
Synergistic antitumor effect of S-1 and the epidermal growth factor
receptor inhibitor gefitinib in non-small cell lung cancer cell
lines: role of gefitinib-induced down-regulation of thymidylate
synthase. Mol Cancer Ther. 7:599–606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wada Y, Yoshida K, Suzuki T, et al:
Synergistic effects of docetaxel and S-1 by modulating the
expression of metabolic enzymes of 5-fluorouracil in human gastric
cancer cell lines. Int J Cancer. 119:783–791. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y
and Hung MC: Co-regulation of B-Myb expression by E2F1 and EGF
receptor. Mol Carcinog. 45:10–17. 2006. View Article : Google Scholar
|
|
34
|
Ginsberg D: EGFR signaling inhibits
E2F1-induced apoptosis in vivo: implications for cancer therapy.
Sci STKE. 2007:pe42007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee KH, Han SW, Hwang PG, et al: Epidermal
growth factor receptor mutations and response to chemotherapy in
patients with non-small-cell lung cancer. Jpn J Clin Oncol.
36:344–350. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takano T, Fukui T, Ohe Y, et al: EGFR
mutations predict survival benefit from gefitinib in patients with
advanced lung adenocarcinoma: a historical comparison of patients
treated before and after gefitinib approval in Japan. J Clin Oncol.
26:5589–5595. 2008. View Article : Google Scholar : PubMed/NCBI
|
